Review of the clinical pharmacokinetics and pharmacodynamics of alemtuzumab and its use in kidney transplantation
M van der Zwan, CC Baan, T van Gelder… - Clinical …, 2018 - Springer
Alemtuzumab is a humanized monoclonal antibody against CD52 and causes depletion of T
and B lymphocytes, monocytes, and NK cells. Alemtuzumab is registered for the treatment of …
and B lymphocytes, monocytes, and NK cells. Alemtuzumab is registered for the treatment of …
Anti-T-cell antibodies for the treatment of acute rejection after renal transplantation
MWF Van den Hoogen, AJ Hoitsma… - Expert opinion on …, 2012 - Taylor & Francis
Introduction: Given the central role of T cells in the alloimmune response, anti-T-cell
antibodies retain a prominent place in the treatment of renal allograft rejection. During the …
antibodies retain a prominent place in the treatment of renal allograft rejection. During the …
[HTML][HTML] Treatment of steroid-resistant acute renal allograft rejection with alemtuzumab
MWF Van Den Hoogen, DA Hesselink… - American journal of …, 2013 - Elsevier
Steroid-resistant renal allograft rejections are commonly treated with rabbit antithymocyte
globulin (RATG), but alemtuzumab could be an effective, safe and more convenient …
globulin (RATG), but alemtuzumab could be an effective, safe and more convenient …
Renal transplantation: Immunosuppression and managing allograft rejection
During its lifetime, the renal allograft is at continuous risk for the development of rejection
due to HLA and non-HLA incompatibility with the recipient which is why lifelong …
due to HLA and non-HLA incompatibility with the recipient which is why lifelong …
Biologics in renal transplantation
R Grenda - Pediatric Nephrology, 2015 - Springer
The biologics used in transplantation clinical practice include several monoclonal and
polyclonal antibodies aimed at specific cellular receptors. The effect of their mechanisms of …
polyclonal antibodies aimed at specific cellular receptors. The effect of their mechanisms of …
CD52-negative NK cells are abundant in the liver and less susceptible to alemtuzumab treatment
R Hotta, M Ohira, T Matsuura, I Muraoka… - PLoS …, 2016 - journals.plos.org
Background T-cell depleting strategies have become an integral part of immunosuppressive
regimens in organ transplantation. Alemtuzumab is a humanized monoclonal antibody …
regimens in organ transplantation. Alemtuzumab is a humanized monoclonal antibody …
Renal transplantation
A Moudgil, SC Jordan - Clinical Pediatric Nephrology, 2016 - taylorfrancis.com
Indications and contraindications to transplantation 743 Donor source 744 Organ
procurement and allocation for children 744 Immunologic barriers to transplantation 745 …
procurement and allocation for children 744 Immunologic barriers to transplantation 745 …
Alemtuzumab (Campath‐1H) therapy for refractory rejections in pediatric heart transplant recipients
B Das, V Dimas, K Guleserian, C Lacelle… - Pediatric …, 2017 - Wiley Online Library
Despite substantial improvements in survival after pediatric heart transplantation, refractory
rejection remains a major cause of morbidity and mortality. We have utilized ALE (Campath …
rejection remains a major cause of morbidity and mortality. We have utilized ALE (Campath …
Primer on renal transplantation
A Moudgil - The Indian Journal of Pediatrics, 2012 - Springer
Renal transplantation transforms chronically ill children with end stage renal disease
(ESRD) into near normal resulting in improvement in nutrition, growth, neurodevelopment …
(ESRD) into near normal resulting in improvement in nutrition, growth, neurodevelopment …
[PDF][PDF] Marieke van der Zwan Carla C. Baan Teun van Gelder
DA Hesselink - … , DIAGNOSIS AND TREATMENT OF ACUTE KIDNEY …, 2020 - core.ac.uk
Background Alemtuzumab is a humanized monoclonal antibody against CD52 and causes
depletion of T and B lymphocytes, monocytes, and NK cells. Alemtuzumab is registered for …
depletion of T and B lymphocytes, monocytes, and NK cells. Alemtuzumab is registered for …